Journal of Thrombosis and Thrombolysis

, Volume 15, Issue 3, pp 205–212

Polymorphism Induced Sensitivity to Warfarin: A Review of the Literature

  • Michael P. Palkimas Jr
  • Hillary M. Skinner
  • Pritesh J. Gandhi
  • Alice J. Gardner
Article

Abstract

Warfarin is a widely prescribed anticoagulant used for prophylaxis and treatment of venous and arterial thrombosis. Although warfarin is considered very efficacious, it has substantial risks associated with its use, specifically the risk of hemorrhage. Genetic variants associated with the metabolism of (S)-warfarin by cytochrome P450 2C9 may have specific implications on untoward effects. Twelve CYP2C9 allelic variants have been identified, of which CYP2C9*3 and CYP2C9*2 are the most clinically important. Studies have demonstrated that initial dosing of warfarin with CYP2C9*3 with a five-milligram dose caused an increase in the international normalized ratio and significant risk of bleeding. Studies conducted with CYP2C9*2, on the other hand are conflicting. Some data suggest that the CYP2C9*2 variant is associated with an increased propensity for bleeding whereas other studies do not demonstrate a substantial risk of adverse events. Researchers suggest that detection of genetic variants in susceptible individuals will not only decrease the risks associated with warfarin therapy but also decrease costs of adverse events.

anticoagulation polymorphism warfarin metabolism genetics CYP2C9 bleeding 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Blann A, Hewitt J, Siddiqui F, et al. Racial background is a determinant of averagewarfarin dose required to maintain the INR between 2.0 and 3.0. British Journal of Haematology 1999;107(1):207-209.Google Scholar
  2. 2.
    Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001;40(8):587-603.Google Scholar
  3. 3.
    Redman A. Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing. Pharmacotherapy 2001;21:235-241.Google Scholar
  4. 4.
    Hirsh J, Dalen J, Anderson D, et al. Oral anticoagulants mechanisms of action, clinical effectiveness, and optimal therapeutic range. Chest 1998;114:445S-469S.Google Scholar
  5. 5.
    Kovacs M, Roger M, Anderson D, et al. Comparison of 10 mg and 5 mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. Ann Intern Med 2003;138:1714-1719.Google Scholar
  6. 6.
    Pirmohamed M. Pharmacogenetics and pharmacogenomics.Br J Clin Pharmacol 2001;52:345-347.Google Scholar
  7. 7.
    Kaminsky L, Zhang Z. Human P450 metabolism of warfarin.Pharmacol Ther 1996;1:67-74.Google Scholar
  8. 8.
    The Human Cytochrome P450 (CYP) Allele Nomenclature Committee. CYP2C9 allele nomenclature. www.imm.ki.se/ CYPalleles/cyp2c9.htm (accessed 2003 May 10).Google Scholar
  9. 9.
    Ingelman-Sundberg M, Oscarson M, McLellan R. Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment. Trends in Pharmacological Sciences 1999;20:342-349.Google Scholar
  10. 10.
    Hirsh J. Optimal intensity and monitoring warfarin. Am J Cardiology 1995;75:39B-42B.Google Scholar
  11. 11.
    Higashi M, Veenstra D, Midori Kondo L, et al.Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.JAMA 2002;287:1690-1698.Google Scholar
  12. 12.
    Tabrizi A, Zehnbaucer B, Borecki I, et al. The frequency and effects of cytochrome P450 2C9 polymorphisms in patients receiving warfarin. The American Journal of Surgeons 2002;194:267-273.Google Scholar
  13. 13.
    Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms onwarfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000;96:1816-1819.Google Scholar
  14. 14.
    Loebstein R, Yonath H, Peleg D, et al. Interindividual variability in sensitivity to warfarin–Nature or nurture? Clin Pharmacol Ther 2001;70:159-164.Google Scholar
  15. 15.
    Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with 212. warfarin dose requirement and risk of bleeding complications.Lancet 1999;353:717-719.Google Scholar
  16. 16.
    Tabrizi A, Mcgrath S, Blinder M, et al. Extreme warfarin sensitivity associated with multiple cytochrome P450 polymorphisms.Am J Hematol 2001;67:144-146.Google Scholar
  17. 17.
    Leung A, Chow H, Kwong Y, et al. Genetic polymorphisms in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients. Blood 2001;98:2584-2587.Google Scholar
  18. 18.
    Hiratsuka M, Agastuma Y, Mizugaki M. Rapid detection of CYP2C9*3 alleles by real-time fluorescence PCR based on SYBR green. Molecular Genetics and Metabolism 1999;68:357-362.Google Scholar
  19. 19.
    Burian M, Grosch S, Tegeder I, et al. Validation of a new flourogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population. Br J Clin Pharmacol 2002;54:518-521.Google Scholar
  20. 20.
    Takahashi H, Kashima T, Kimura S, et al. Determination of unbound warfarin enantiomers in human plasma and 7-hydroxywarfarin in human urine by chiral stationaryphase liquid chromatography with ultraviolet or fluorescence and on-line circular dichroism detection. Journal of Chromatography B 1997;701:71-80.Google Scholar
  21. 21.
    Lafata J, Martin S, Kaatz S, et al. The cost-effectiveness of different management for patients on chronic warfarin therapy. J Gen Intern Med 2000;15:31-37.Google Scholar
  22. 22.
    Ross J, Ginsburg G. The integration of molecular diagnostics with therapeutics. Am J Clin Pathol 2003;119(1):26-36.Google Scholar

Copyright information

© Kluwer Academic Publishers 2003

Authors and Affiliations

  • Michael P. Palkimas Jr
    • 1
  • Hillary M. Skinner
    • 1
  • Pritesh J. Gandhi
    • 1
  • Alice J. Gardner
    • 1
    • 2
  1. 1.Massachusetts College of Pharmacy and Health Sciences—WorcesterUSA
  2. 2.Pharmacology/ToxicologyMassachusetts College of Pharmacy and Health Sciences—WorcesterUSA

Personalised recommendations